Bulletin
Investor Alert

Intra-Cellular Therapies Inc.

NAS: ITCI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Intra-Cellular Therapies Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 31, 2023, 5:00 p.m.

ITCI
/zigman2/quotes/209441868/composite

$

47.92

Change

0.00 0.00%

Volume

Volume 203,558

Quotes are delayed by 20 min

/zigman2/quotes/209441868/composite

Today's close

$ 46.99

$ 47.92

Change

+0.93 +1.98%

Day low

Day high

$47.35

$48.79

Open

52 week low

52 week high

$42.42

$66.00

Open

Company Description

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the centra...

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Valuation

Price to Sales Ratio

50.75

Price to Book Ratio

10.26

Enterprise Value to EBITDA

-14.24

Enterprise Value to Sales

21.59

Efficiency

Total Asset Turnover

0.14

Liquidity

Current Ratio

8.76

Quick Ratio

8.61

Cash Ratio

7.75

Profitability

Gross Margin

90.41

Operating Margin

-340.90

Pretax Margin

-339.03

Net Margin

-339.04

Return on Assets

-47.07

Return on Equity

-52.87

Return on Total Capital

-50.60

Capital Structure

Total Debt to Total Assets

5.19

Officers and Executives

Name Age Officer Since Title
Dr. Sharon Mates 68 2013 Chairman, President & Chief Executive Officer
Mr. Lawrence J. Hineline 63 2013 Chief Financial Officer & Senior VP-Finance
Dr. Robert E. Davis 68 2015 Chief Scientific Officer & Senior Vice President
Dr. Suresh Durgam - - Senior Vice President-Medical Affairs
Ms. Karen Patruno Sheehy 57 2019 Chief Compliance Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/30/2022 Rory Balfour Riggs
Director 		321   Award at $52.92 per share. 16,987
12/19/2022 Joel S. Marcus
Director 		5,000   Disposition at $50.82 per share. 254,100
12/13/2022 Sharon Mates
Chairman, President & CEO; Director 		33,083   Disposition at $55 per share. 1,819,565
12/01/2022 Michael Halstead
EVP and General Counsel 		22,796   Disposition at $53.48 per share. 1,219,130
12/01/2022 Michael Halstead
EVP and General Counsel 		27,204   Disposition at $53.94 per share. 1,467,383
12/01/2022 Michael Halstead
EVP and General Counsel 		50,000   Derivative/Non-derivative trans. at $15.47 per share. 773,500
11/07/2022 Joel S. Marcus
Director 		5,000   Disposition at $52.11 per share. 260,550
11/07/2022 Joel S. Marcus
Director 		5,000   Disposition at $52.49 per share. 262,450
09/30/2022 Rory Balfour Riggs
Director 		365   Award at $46.53 per share. 16,983
09/30/2022 Robert L. van Nostrand
Director 		110   Award at $46.53 per share. 5,118
09/21/2022 Lawrence J. Hineline
SVP of Finance CFO 		33,303   Disposition at $45.39 per share. 1,511,623
09/21/2022 Lawrence J. Hineline
SVP of Finance CFO 		31,861   Disposition at $45.88 per share. 1,461,782
09/21/2022 Lawrence J. Hineline
SVP of Finance CFO 		65,164   Derivative/Non-derivative trans. at $15.47 per share. 1,008,087
08/11/2022 Joel S. Marcus
Director 		10,000   Disposition at $59.22 per share. 592,200
08/11/2022 Robert L. van Nostrand
Director 		1,500   Disposition at $56.8 per share. 85,200
08/11/2022 Robert L. van Nostrand
Director 		28,500   Disposition at $57.15 per share. 1,628,775
08/11/2022 Robert L. van Nostrand
Director 		10,000   Derivative/Non-derivative trans. at $13.05 per share. 130,500
08/11/2022 Robert L. van Nostrand
Director 		20,000   Derivative/Non-derivative trans. at $12.45 per share. 249,000
06/30/2022 Rory Balfour Riggs
Director 		289   Award at $57.08 per share. 16,496
06/30/2022 Robert L. van Nostrand
Director 		108   Award at $57.08 per share. 6,164
05/12/2022 Joel S. Marcus
Director 		10,000   Disposition at $55 per share. 550,000
/news/latest/company/us/itci

MarketWatch News on ITCI

  1. Thematic ETFs Look Tempting. Just Say No.

    4:01 p.m. Dec. 12, 2022

    - Barron's Online

  2. Intra-Cellular Therapies started at buy with $74 stock price target at Mizuho

    6:06 a.m. July 7, 2022

    - Tomi Kilgore

  3. Intra-Cellular Therapies started at buy with $75 stock price target at UBS

    9:52 a.m. June 14, 2022

    - Tomi Kilgore

  5. The FDA Is About to Make Some Major Drug Decisions

    1:51 p.m. Oct. 16, 2021

    - Barron's Online

  7. Intra-Cellular Therapies downgraded to neutral from overweight at J.P. Morgan

    7:54 a.m. Jan. 31, 2020

    - Tomi Kilgore

  8. Intra-Cellular Therapies stock price target raised to $65 vs. $29 at Canaccord

    10:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  9. Intra-Cellular Therapies reiterated as buy at Canaccord

    10:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  12. Intra-Cellular Therapies gets FDA approval for schizophrenia treatment

    7:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  13. Intra-Cellular Therapies stock soars 42% premarket

    7:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  15. Intra-Cellular Therapies shares slide 7% after resuming trade following halt.

    6:36 a.m. July 8, 2019

    - Ciara Linnane

  17. Intra-Cellular announces positive results in late-stage trial of treatment for bipolar depression

    6:05 a.m. July 8, 2019

    - Ciara Linnane

  18. Intra-Cellular Therapies and Sol-Gel Technologies halted for news pending

    5:58 a.m. July 8, 2019

    - Ciara Linnane

  21. Loading more headlines...
/news/nonmarketwatch/company/us/itci

Other News on ITCI

  4. Top 5 3rd Quarter Trades of GW&K Investment Management, LLC

    2:00 p.m. Nov. 9, 2022

    - GuruFocus.com

  12. Intra-Cellular Therapies Q3 2022 Earnings Preview

    12:39 p.m. Nov. 2, 2022

    - Seeking Alpha

  13. Lisanti Capital Growth, LLC Buys 2, Sells 3 in 3rd Quarter

    8:00 a.m. Nov. 2, 2022

    - GuruFocus.com

  17. Intra-Cellular Therapies: What Lies Ahead

    6:45 p.m. Sept. 20, 2022

    - Seeking Alpha

  18. Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

    12:31 p.m. Sept. 16, 2022

    - Seeking Alpha

  19. Warning: ITCI is at high risk of performing badly

    3:51 a.m. Sept. 9, 2022

    - Seeking Alpha

  20. Warning: ITCI is at high risk of performing badly

    1:50 a.m. Aug. 31, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Intra-Cellular Therapies, Inc.

430 East 29th Street

Suite 900

New York, New York 10016

Phone

1 4644409333

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$83.80M

Net Income

$-284.13M

Employees

512.00

Annual Report for ITCI

/news/pressrelease/company/us/itci

Press Releases on ITCI

  12. What Stocks To Buy This Week? 4 Biotech Stocks To Know

    10:20 a.m. May 15, 2022

    - StockMarket.com

  21. Loading more headlines...
Link to MarketWatch's Slice.